Originally published Oct. 8.

By Turna Ray

A recently published
meta-analysis that sheds doubt on the validity of the KIF6 variant as a pharmacogenomic cardiac biomarker has inspired an editorial from two cardiologists cautioning test developers and investigators from rushing to market with gene markers with limited clinical validity.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: dynamics of protein profusion and localization, melanoma classification schemes, and more.

A company says it can generate likenesses of people based on their genetic profiles.

IBM's Watson is learning how to treat leukemia as a fellow at the MD Anderson Cancer Center, according to the Washington Post.

Researchers report that what scents someone picks up can reflect their complement of immune genes.